Sulindac
- Generic Name
- Sulindac
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17FO3S
- CAS Number
- 38194-50-2
- Unique Ingredient Identifier
- 184SNS8VUH
- Background
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted in vivo to an active sulfide compound by liver e...
- Indication
For acute or long-term use in the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder (acute subacromial bursitis/supraspinatus tendinitis), and acute gouty arthritis.
- Associated Conditions
- Ankylosing Spondylitis (AS), Colorectal Adenomas, Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Tendonitis exacerbated, Acute Subacromial bursitis, Acute supraspinatus tendinitis
- Associated Therapies
- -
Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01856322
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Sulindac for Patients With AML
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01843179
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
NSAID Effects on Clinical and Imaging Breast Biomarkers
- First Posted Date
- 2013-01-07
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Stony Brook University
- Target Recruit Count
- 114
- Registration Number
- NCT01761877
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Stony Brook University Cancer Center, Stony Brook, New York, United States
Urinary Biomarker Study With Sulindac and Difluoromethylornithine
- Conditions
- Interventions
- First Posted Date
- 2012-07-10
- Last Posted Date
- 2014-07-30
- Lead Sponsor
- Cancer Prevention Pharmaceuticals, Inc.
- Registration Number
- NCT01636128
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis Patients
- Conditions
- Interventions
- First Posted Date
- 2010-08-24
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 92
- Registration Number
- NCT01187901
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Sulindac in Preventing Melanoma in Healthy Participants Who Are at Increased Risk of Melanoma
- Conditions
- Interventions
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2017-12-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00841204
- Locations
- 🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States
🇺🇸Stanford University Hospitals and Clinics, Stanford, California, United States
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
- Conditions
- Interventions
- First Posted Date
- 2008-09-19
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Cancer Trials Ireland
- Target Recruit Count
- 32
- Registration Number
- NCT00755976
- Locations
- 🇮🇪
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital, Dublin, Ireland
🇮🇪Cork University Hospital, Cork, Ireland
🇮🇪Mater Misericordiae University Hospital, Dublin, Ireland
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00392665
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Sulindac in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
- Conditions
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2014-05-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT00368927
- Locations
- 🇨🇦
British Columbia, Vancouver, British Columbia, Canada
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Sulindac Capsules Compared With Sulindac Tablets in Healthy Volunteers
- Conditions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 28
- Registration Number
- NCT00343629
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.